MedAmicus
This article was originally published in The Gray Sheet
Executive Summary
Retractable needle technology developer Med-Design receives $1 mil. in MedAmicus common stock in partial payment for MedAmicus' $2 mil. obligation under a Sept. 10 license agreement addendum. The addendum grants MedAmicus an exclusive license to use Med-Design's retractable needle technology in the arterial access market and related fields. MedAmicus plans to pay an additional $1 mil. in cash on Oct. 15. The original August 2000 licensing pact relates to the venous market. Separately, MedAmicus reported Oct. 11 that third quarter sales doubled to $3.7 mil. The Minneapolis firm cites expanding sales of introducer products, including left-heart lead delivery systems for use with Medtronic's recently approved InSync cardiac resynchronization therapy for congestive heart failure
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.